The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China.,Clinical Immunology

当前位置： X-MOL 学术 › Clin. Immunol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China.
Clinical Immunology ( IF 8.6 ) Pub Date : 2020-03-25 , DOI: 10.1016/j.clim.2020.108393
Wen Zhang ₁ , Yan Zhao ₁ , Fengchun Zhang ₁ , Qian Wang ₁ , Taisheng Li ₂ , Zhengyin Liu ₃ , Jinglan Wang ₄ , Yan Qin ₅ , Xuan Zhang ₆ , Xiaowei Yan ₇ , Xiaofeng Zeng ₁ , Shuyang Zhang ₇

Affiliation

Department of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences (CAMS), Peking Union Medical College Hospital, The Ministry of Education Key Laboratory, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing 100730, China.
Clinical Immunology Centre, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100730, China; Department of Infectious Disease, Chinese Academy of Medical Sciences (CAMS), Peking Union Medical College Hospital, Beijing 100730, China; Intensive Care Unit (ICU) for COVID-19, Wu Han Tong Ji Hospital, Wuhan City, Hubei Province 200065, China.
Department of Infectious Disease, Chinese Academy of Medical Sciences (CAMS), Peking Union Medical College Hospital, Beijing 100730, China; Intensive Care Unit (ICU) for COVID-19, Wu Han Tong Ji Hospital, Wuhan City, Hubei Province 200065, China.
Department of Respiratory Medicine, Chinese Academy of Medical Sciences (CAMS), Peking Union Medical College Hospital, Beijing 100730, China; Intensive Care Unit (ICU) for COVID-19, Wu Han Tong Ji Hospital, Wuhan City, Hubei Province 200065, China.
Department of Nephrology, Chinese Academy of Medical Sciences (CAMS), Peking Union Medical College Hospital, Beijing 100730, China; Intensive Care Unit (ICU) for COVID-19, Wu Han Tong Ji Hospital, Wuhan City, Hubei Province 200065, China.
Department of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences (CAMS), Peking Union Medical College Hospital, The Ministry of Education Key Laboratory, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing 100730, China; Clinical Immunology Centre, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100730, China.
Department of Cardiology, Chinese Academy of Medical Sciences (CAMS), Peking Union Medical College Hospital, Beijing 100730, China; Intensive Care Unit (ICU) for COVID-19, Wu Han Tong Ji Hospital, Wuhan City, Hubei Province 200065, China.

The pandemic outbreak of coronavirus disease 2019 (COVID-19) is rapidly spreading all over the world. Reports from China showed that about 20% of patients developed severe disease, resulting in a fatality of 4%. In the past two months, we clinical immunologists participated in multi-rounds of MDT (multidiscipline team) discussion on the anti-inflammation management of critical COVID-19 patients, with our colleagues dispatched from Chinese leading PUMC Hospital to Wuhan to admit and treat the most severe patients. Here, from the perspective of clinical immunologists, we will discuss the clinical and immunological characteristics of severe patients, and summarize the current evidence and share our experience in anti-inflammation treatment, including glucocorticoids, IL-6 antagonist, JAK inhibitors and choloroquine/hydrocholoroquine, of patients with severe COVID-19 that may have an impaired immune system.

更新日期：2020-03-26

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南

全部期刊列表>>